https://www.selleckchem.com/products/vh298.html
05), but OS and EFS were not different statistically. CCR rates did not differ for AZA-VEN vs. DEC-VEN (CCR 58% vs. 52%, P=0.66), but OS and EFS were longer for AZA-VEN (m-OS 12.3 vs. 2.2 months, P less then 0.05; m-EFS 9.2 vs. 2.1 months, P less then 0.05). Our analysis showed that combining VEN with AZA in newly diagnosed AML patients improved outcomes, but combining VEN with DEC did not. AZA-VEN was associated with improved outcomes compared to DEC-VEN. Further studies are needed to test the benefit of combining VEN with DEC. This stud